Antea Participaties

Antea Participaties is a private equity and venture capital firm based in The Hague, Netherlands, founded in 1999. It focuses on middle-market investments and growth opportunities, backing B2B and B2C businesses across sectors such as food, industry, ICT, media and business services, with a regional emphasis on the Netherlands. The firm typically targets investments of about €1.5 million to €7.5 million in companies with enterprise values of €5 million to €30 million and EBITDA of at least €1 million, and it can take either minority or majority stakes, aiming for exits in five to seven years. Its portfolio spans consumer products, industrials, technology-enabled services and related sectors that leverage the Dutch market focus.

Coen Binnerts

Business Analyst

Robert de Boeck

Founder, Director and Managing Partner

Maarten Herreveld

Investment Manager

Roelant Scheepens

Partner

Pieter Wilde RC

Partner and Director

3 past transactions

Fresh Cans

Acquisition in 2019
Fresh Cans, based in Utrecht, Netherlands, offers management consulting services that address modern challenges faced by organizations. The company focuses on employer branding, talent acquisition, and development, as well as strategy and brand activation. By employing young professionals with entrepreneurial spirit, Fresh Cans aims to assist large organizations in transforming, innovating, and accelerating their operations. Through its tailored services, the firm helps clients navigate complex business landscapes and enhance their overall performance.

Uniekaas

Acquisition in 2014
Uniekaas, established in 1965, is a Dutch cheese producer renowned for its high-quality Gouda cheese. With roots tracing back to De KaasUnie, a cooperative of regional cheese traders founded in 1956, Uniekaas operates from its production facility in Kaatsheuvel. The company specializes in producing, maturing, cutting, packaging, and selling cheese products under its own fixed recipes, ensuring no artificial additives or preservatives are used.

to-BBB

Series B in 2011
to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® for enhanced drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases is completing a Phase I clinical study. to-BBB is headquartered in the Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.